Trial Profile
A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-7 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms PLEIADES
- 03 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov. (NCT00099671)
- 03 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov. (NCT00099671)
- 03 May 2012 Actual patient number changed from 16 to 25 as reported by ClinicalTrials.gov (NCT00099671)